about
Single-center, noninterventional clinical trial to assess the safety, efficacy, and tolerability of a dimeticone-based medical device in facilitating the removal of scales after topical application in patients with psoriasis corporis or psoriasis caTargeting IL-23 in psoriasis: current perspectives.Drug-induced psoriasis: clinical perspectives.Monitoring treatment response in psoriasis: current perspectives on the clinical utility of reflectance confocal microscopy.Psoriasis and inflammatory bowel disease: links and risks.Psoriasis patients' experiences concerning medical adherence to treatment with topical corticosteroids.Psoriasis and smoking: links and risks.The metabolomics of psoriatic disease.Excimer laser for the treatment of psoriasis: safety, efficacy, and patient acceptability.Links and risks associated with psoriasis and metabolic syndrome.Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management.Herpes zoster in psoriasis patients undergoing treatment with biological agents: prevalence, impact, and management challenges.Management of scalp psoriasis: current perspectives.Improving patient outcomes in psoriasis: strategies to ensure treatment adherence.Subcutaneous methotrexate for symptomatic control of severe recalcitrant psoriasis: safety, efficacy, and patient acceptability.Fumaric acid esters in the management of psoriasis.Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability.Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis.Psoriasis in children.Erythrodermic psoriasis: pathophysiology and current treatment perspectives.Tacrolimus for the management of psoriasis: clinical utility and place in therapy.Improving access to home phototherapy for patients with psoriasis: current challenges and future prospects.Current knowledge on psoriasis and autoimmune diseases.Psoriasis in childhood: effective strategies to improve treatment adherence.Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography.Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry.Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic review.Combining biologic and phototherapy treatments for psoriasis: safety, efficacy, and patient acceptability.Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management.Assessment and monitoring of biologic drug adverse events in patients with psoriasis.Update on the treatment of psoriasis and psoriatic arthritis - role of apremilast.Epidemiology and treatment of psoriasis: a Brazilian perspective.Optimal management of nail disease in patients with psoriasis.Pustular psoriasis: pathophysiology and current treatment perspectives.Local effects of adipose tissue in psoriasis and psoriatic arthritis.Integrating lifestyle-focused approaches into psoriasis care: improving patient outcomes?Psoriasis in pregnancy: challenges and solutions.Clinical potential of brodalumab in the management of psoriasis: the evidence to date.Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives
P1433
Q51756478-B6A39AE9-7FD4-484C-A759-1D101E8B3E7AQ52695350-58C7558F-A475-4823-96B8-DEBED7E6DEE8Q52701370-4CB8ED29-4D3B-4450-AC6C-0CEF294F5801Q52701373-1DF17274-5717-4075-8DA3-619EC1465ADFQ52859380-3C7C3CD0-3862-4984-8588-2C2304A0D5E1Q53031448-B0DDAE3F-F79D-4EEF-9058-3FD4CCAD10BFQ53080454-1E29223A-B2C9-4ACA-83E2-BBEED91CC9C2Q53103335-CC2E878C-4A6F-4E30-BBF2-742E52AB0BE5Q53639312-64DBBC89-DC48-4C94-A1EF-71218DEE7ECDQ53811311-9C0DB8B5-91FF-4FB7-82A4-0E86AF4F924EQ54279289-625D11C0-B82F-4A6A-AF4E-0BB4E63A6FE5Q54508929-2B0D2DE9-288A-429B-8185-65A31BD4AF46Q54941753-0137DDFC-82BF-497D-96E7-986C8885733AQ54943839-90E8141F-6A17-4E49-9D9C-21C98EA0A933Q54956831-14AEC36A-DFC0-41B0-8EA9-A9D81D62EFE3Q54958047-346711F8-E7B3-4DED-8BD7-BA84D252F3F8Q54973760-C2DD7D39-3059-4B3E-ACB3-244546CE9A60Q55000976-F5CD9C5D-4F29-4CD2-BDD5-585BCA7D672CQ55006126-FE6B260A-E50F-415E-AEB4-096870E3C5DDQ55020325-2C2326F5-8F1A-4CEE-82CE-20DDE038297FQ55023453-21673A99-2BC3-4F8C-AE31-98171C652F91Q55026311-CA1BE3B8-CC21-4AA0-A35B-8D8B5A9CBFB1Q55044800-56A7987F-0B03-4877-AED8-992680F4ADD6Q55045498-49EF879B-59E0-4BFA-9C01-65C3ADED30DAQ55082101-F2F3EB97-7108-45FA-8505-4C60B752047EQ55085175-8F586A15-140F-43C7-B1C0-1EA64DBDE242Q55101112-94C791D5-5D4D-4ECF-BF8A-BA66D49861D9Q55109332-404F3FAD-020A-4745-B2A1-D734E2300164Q55119166-F38F2A89-F815-4CBC-9E2B-8952A858E696Q55152453-D89A77FF-BB95-4A0D-A004-73CAFA901141Q55153984-E206B546-E766-4850-B881-C95C20095351Q55177045-BFEEC052-28D4-406B-B7BE-2174A967C738Q55181442-4C7BCDAA-6304-4945-8877-F44B9F3D476AQ55192665-5970147D-AB24-4ECF-B07E-7EA8373D321CQ55401560-82160A96-65EF-4D2F-98E7-DF859B4617ADQ55440359-BA2A2A84-29D2-42E0-B0A4-75BE0DCF2564Q55547911-AF512663-C902-4705-AA0C-BFE8803E11FBQ55553649-94B30CAD-54A7-4D12-9383-8CFFEF8E012CQ55715868-CC1B7348-2313-47F0-A987-8EBBC2E6FF2BQ56891106-F36CD33F-7B9A-48E0-B37C-349DCF063A0E
P1433
description
Academic journal published by ...... ecialties of internal medicine
@en
academisch tijdschrift
@nl
name
Psoriasis : Targets and Therapy
@en
Psoriasis : Targets and Therapy
@nl
type
label
Psoriasis : Targets and Therapy
@en
Psoriasis : Targets and Therapy
@nl
altLabel
Psoriasis : Targets & Therapy
@en
prefLabel
Psoriasis : Targets and Therapy
@en
Psoriasis : Targets and Therapy
@nl
P1055
P1156
21100787794